- Organizations: Glaukos
Legal
FDA scrutiny of unapproved CXL trials reveals critical lapses in patient safety and regulatory adherence
Clinicians’ failure to follow federal regulations with unapproved drugs sparks discussion on legal and ethical concerns.
Products
Glaukos and RadiusXR partner with Topcon on VF testing platform
Collaboration involves the launch of RadiusXR’s new wearable vision testing platform, the first tech of its kind to combine visual fields correlated to the clinical standard.
Pipeline
FDA accepts NDA submission for Glaukos's Epioxa
Epi-on CXL iLink therapy could become the first noninvasive procedure with no need for corneal epithelium removal to treat keratoconus eyes.
Pipeline
Glaukos reports positive IOP-lowering clinical data on iDose platform
Latest update includes 36-month follow-up; phase 4 results on iDose TR with cataract surgery; and a new phase 2b/3 study on a next-gen implant.Pipeline
Glaukos submits Epioxa NDA for keratoconus
Next-gen corneal cross linking therapy could become the first to not require removal of the corneal epithelium.Pipeline
Glaukos reports phase 3 topline data on Epioxa for keratoconus
Findings will support an anticipated NDA submission for the second-generation iLink therapy by the end of 2024.
Business
Nicox and Glaukos sign global licensing option for glaucoma and retinal candidate
Agreement includes preclinical research for NCX 1728, the lead compound of a new class of nitric-oxide-donating molecule class.
Products
J-Code for Glaukos' iDose TR takes effect
Permanent reimbursement code is intended to simplify and ensure consistent coverage for OAG and OHT patients across the U.S.
Research
Sight Sciences reports real-world data on leading MIGS devices, including OMNI Surgical System
Large-scale, comparative study also evaluated the Hydrus Microstent and iStent inject for lowering IOP in 100,000+ glaucoma patients’ eyes.Pipeline
Travoprost implant shows robust IOP-lowering in phase 3 study
Phase 3 trial finds travoprost implant as safe and effective alternative to topical IOP-lowering meds.Products
Glaukos' iDose TR implant assigned permanent J-code
Effective July 1, the micro-invasive and injectable treatment will have a permanent reimbursement.
Research
iStent inject with cataract surgery may reduce glaucoma meds
iStent Inject demonstrates clinically and statistically significant reduction in glaucoma medications at 2 years.
Products
Glaukos' iDose TR intracameral launches in the US
MIGS sustained-release device is designed as a longer duration treatment indicated to reduce IOP in OHT and OAG patients.Products
FDA approves Glaukos' iDose TR intracameral implant
With long-term durability, the micro-invasive and injectable treatment is indicated to reduce IOP in OHT and OAG patients.
Pipeline
Glaukos acquires global rights to Stuart Therapeutics' neuroprotection glaucoma asset
Proprietary therapeutic has been shown to function independently of IOP control.
Research
iDetective campaign targets early keratoconus diagnosis
Optometrist-focused initiative advocates for game-changing patient care.
Business
Glaukos partners with Radius XR on wearable diagnostic system
The portable vision diagnostic and patient engagement system is designed to detect and manage eye diseases.
Events
Glaukos campaign targets keratoconus prevention among young adults
“The Rub” aims to raise awareness of keratoconus and its link to eye rubbing.
Pipeline
Glaukos completes enrollment of phase 3 corneal CXL trial for keratoconus
Secondary phase 3 pivotal trial is assessing Epioxa (Epi-on); data will support an eventual NDA submission.
Products